Sheaff Brock Investment Advisors LLC Sells 2,048 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Sheaff Brock Investment Advisors LLC cut its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 7.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,067 shares of the biopharmaceutical company’s stock after selling 2,048 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Bristol Myers Squibb were worth $1,651,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Capital City Trust Co. FL boosted its holdings in Bristol Myers Squibb by 3.8% in the 1st quarter. Capital City Trust Co. FL now owns 19,994 shares of the biopharmaceutical company’s stock valued at $1,219,000 after purchasing an additional 725 shares during the period. Peak Asset Management LLC boosted its holdings in Bristol Myers Squibb by 1.0% in the 1st quarter. Peak Asset Management LLC now owns 38,139 shares of the biopharmaceutical company’s stock valued at $2,326,000 after purchasing an additional 375 shares during the period. MRP Capital Investments LLC boosted its holdings in Bristol Myers Squibb by 8.0% in the 1st quarter. MRP Capital Investments LLC now owns 10,108 shares of the biopharmaceutical company’s stock valued at $616,000 after purchasing an additional 750 shares during the period. Waddell & Associates LLC bought a new position in Bristol Myers Squibb in the 1st quarter valued at $250,000. Finally, Atlantic Family Wealth LLC raised its position in shares of Bristol Myers Squibb by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 5,921 shares of the biopharmaceutical company’s stock valued at $361,000 after buying an additional 250 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $55.00 price objective (down from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Morgan Stanley dropped their price objective on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an “underweight” rating for the company in a report on Thursday, July 10th. Wall Street Zen downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. William Blair reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Friday, April 25th. Finally, UBS Group dropped their price objective on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a report on Friday, April 11th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $58.53.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $48.44 on Monday. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. The firm has a market cap of $98.57 billion, a price-to-earnings ratio of 18.14, a price-to-earnings-growth ratio of 2.53 and a beta of 0.36. The company has a 50 day moving average price of $47.67 and a 200-day moving average price of $52.59. Bristol Myers Squibb Company has a 1-year low of $44.00 and a 1-year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The business’s quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($4.40) EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.12%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb’s payout ratio is presently 92.88%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.